复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎伴脾肿大患者疗效观察

发布时间：2018-05-21 07:40

本文选题：慢性乙型肝炎 + 脾肿大　；参考：《中国现代医学杂志》2017年02期

【摘要】：目的观察复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎伴脾肿大的临床疗效。方法选取125例慢性乙型肝炎伴脾肿大患者。随机分为治疗组和对照组,治疗组70例给予复方鳖甲软肝片联合恩替卡韦治疗,对照组仅给予恩替卡韦治疗,用药12个月后分别评价比较治疗前后肝功能、血常规、彩超、肝硬度值和疗效的变化。结果两组患者治疗后血常规三系上升,脾功能亢进较前改善,但差异无统计学意义(P0.05);肝功能TBIL、ALT改善程度、脾脏缩小程度上差异有统计学意义(P0.05),治疗组变化更明显,治疗后两组差异有统计学意义(P0.05);治疗组门静脉宽度下降明显,治疗前后差异有统计学意义(P0.05);肝脏硬度值均下降,差异均有统计学意义(P0.05),治疗组下降更明显,治疗后两组差异有统计学意义(P0.05);治疗组有效率达到91.4%,与对照组比较,差异有统计学意义(P0.05)。结论复方鳖甲软肝片联合恩替卡韦治疗,能有效阻断和延缓慢性乙型肝炎伴脾肿大患者肝纤维化的发生与进展,同时提高疗效,改善患者肝功能。
[Abstract]:Objective to observe the clinical effect of compound Biejia Ruangan tablet combined with entecavir in the treatment of chronic hepatitis B with splenomegaly. Methods 125 patients with chronic hepatitis B with splenomegaly were selected. They were randomly divided into treatment group and control group. 70 cases in treatment group were treated with compound Biejia Ruangan tablet combined with entecavir, while the control group was treated only with entecavir. After 12 months of treatment, liver function, blood routine examination, color Doppler ultrasound were evaluated, respectively. Changes of liver hardness and efficacy. Results after treatment, the blood routine of the two groups increased, the hypersplenism was improved, but the difference was not statistically significant (P 0.05), the improvement of liver function TBILT and the degree of spleen shrinking were significantly different (P 0.05), and the change of the treatment group was more obvious than that of the control group. After treatment, there was a significant difference between the two groups (P 0.05), the width of portal vein in the treatment group decreased significantly, and the difference before and after treatment was statistically significant (P 0.05), and the liver hardness decreased significantly (P 0.05), especially in the treatment group. After treatment, the difference between the two groups was statistically significant (P 0.05), and the effective rate of the treatment group reached 91.4%, compared with the control group, the difference was statistically significant (P 0.05). Conclusion compound Biejia Ruanggan tablets combined with entecavir can effectively block and delay the occurrence and progress of liver fibrosis in patients with chronic hepatitis B and splenomegaly, and improve the curative effect and liver function.
【作者单位】：陕西省渭南市中心医院感染病科;
【分类号】：R512.62

【参考文献】